ArticleOrganogenesis2007
The KIDSTEM European Research Training Network: Developing a Stem Cell Based Therapy to Replace Nephrons Lost through Reflux Nephropathy.
Article in Organogenesis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
- Human Muscle Precursor Cells Overexpressing PGC-1α Enhance Early Skeletal Muscle Tissue Formation.Cell transplantation · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and prevalence of end stage renal disease (ESRD) continues to grow worldwide at a rate that is far in excess of the growth rate of the general population. In children and young adults the most common cause of ESRD is vesicoureteric reflux (VUR), a condition where urine from the bladder re-enters the kidney, predisposing to pyelonephritis, renal scarring, and in the most severe cases, ESRD. However, there is usually a time-window of several years from initial diagnosis of VUR to the development of ESRD, which presents an opportunity to design therapies aimed at preventing disease progression by repairing renal tissue before it becomes nonfunctional. Advances in our understanding of kidney development coupled with recent progress in stem cell science and tissue engineering, present an unprecedented opportunity to design a stem cell-based therapy for this clinical problem. KIDSTEM will investigate the properties of several different stem cell types (kidney stem cells, embryonic stem cells, amniotic fluid stem cells and mesenchymal stem cells) to determine which is most appropriate for the generation of functional renal tissue promoted by specifically designed biomaterials to facilitate the generation of functional nephrons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.